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1.

Introduction
For the last 100 yr, treatments for localised prostate cancer have had the whole prostate as their therapeutic target. The utility of a whole-organ approach to prostate cancer treatment has recently been brought into question. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) failed to demonstrate an overall statistically significant survival benefit associated with radical prostatectomy when compared to a conservative strategy [1] , although survival benefits were seen in the intermediate-and high-risk subgroups. This confirmed the findings from the Scandinavian Prostate Cancer Group SPCG-4 trial of watchful waiting versus radical prostatectomy in men with high-risk prostate cancer [2] . However, the risk of incontinence and erectile dysfunction associated with radical whole-gland therapy is 15-20% and 30-60%, respectively [3] , with significant other complications [4] .
Focal therapy involves targeting individual areas of cancer while preserving the majority of the prostate tissue and therefore minimising the collateral damage to surrounding structures such as the external urinary sphincter, bladder neck, neurovascular bundles, and rectum [5, 6] . Support comes from studies in which tissue preservation was applied but all known cancer was targeted [7] [8] [9] . These studies had very low side-effect profiles and cancer-free rates consistently between 80% and 90%.
Concern regarding focal therapy has centred on the knowledge that prostate cancer is multifocal in origin. In prostate cancer, a larger dominant lesion is often accompanied by two or three smaller low-grade lesions. A hypothesis has emerged that the largest lesion in the prostate-the index lesion-drives disease progression [10] . The index lesion tends to be associated with the highest Gleason grade, harbours other pathological determinants of progression, and has been associated with lymph node metastases on genetic profiling [11, 12] . If the index lesion could be isolated with reasonable precision and treatment directed to it alone, then the oncological efficacy of whole-gland treatment might be matched while minimising the risk of side effects. To the best of our knowledge, this is the first prospective study testing this hypothesis.
2.
Patients and methods
Study design and conduct
Our single-centre study was a prospective development study according to the IDEAL (Idea, Development, Exploration, Assessment, and Longterm) guidelines for evaluating innovation in surgery [13] . The trial was approved by Local Research Ethics Committee A of the University College London Hospitals. 20 ng/ml, Gleason 4 + 3, stage T3aN0M0) were eligible ( Fig. 1 ).
Patient population
Study interventions
Cancer localisation
Prostate cancer was localised using multiparametric magnetic resonance imaging (mpMRI) and transperineal template prostate mapping (TPM)
biopsies [14] (n = 24) and/or transrectal ultrasound (TRUS)-guided biopsies (n = 22). TPM biopsies were carried out under general or spinal anaesthesia, with the prostate sampled at 5-mm intervals.
The index lesion was identified according to the following criteria.
First, if an mpMRI lesion was visible on at least two sequences (equivalent to Prostate Imaging Reporting and Data System score of 4 or 5), the dominant biopsy findings had to be concordant with that lesion location. Second, the dominant histological lesion was assigned in the following manner whether an mpMRI lesion was present or not (TPM biopsies were required if an mpMRI lesion was not present):
(1) If the prostate only harboured Gleason 6 disease, then the index lesion was the lesion with the maximum cancer core length (CCL max ) provided all other lesions on biopsy located in another quadrant of the prostate had CCL max 5 mm.
(2) If there was grade heterogeneity between individual lesions, then the lesion with the highest Gleason grade was regarded as the index lesion provided it had no more than Gleason 4 + 3 and the other lesions had no more than Gleason 3 + 3 AND CCL max 5 mm.
Treatment
Focal ablation of the index lesion was performed using transrectal high- 
Follow-up
Contrast-enhanced MRI was carried out at 10-14 d to evaluate the area of ablation, demonstrated by a confluent perfusion deficit ( Fig. 3) .
Clinical review at 1, 3, 6, 9, and 12 mo assessed adverse events, serum PSA, and responses to validated questionnaires. Phosphodiesterase-5
inhibitor (PDE5-I) use was permitted at any time point before treatment and during follow-up to aid erectile function. At 6 mo, mpMRI followed by biopsies targeted to the treated area was scheduled, with a minimum sampling requirement of one core for every 1 ml of residual tissue.
Repeat treatment using focal HIFU for treated or untreated areas that
Patient summary: In this study we looked at whether it is possible to treat the largest and highest-grade tumour in men who have more than one known prostate tumour. We show that the side effects of targeted ablation were low, with acceptable rates of early cancer control. Larger studies with longer follow-up are needed. showed signs of progression was permitted if biopsies were positive.
Further mpMRI was carried out at 12 mo in such cases. As the purpose of the 6-mo biopsies was to determine whether the ablation was successful, our ethics committee did not permit transperineal TPM biopsies of untreated tissue because of the requirement for another general anaesthetic. However, biopsies of untreated tissue were permitted if a new lesion suspicious for cancer was seen on mpMRI or if existing untreated tissue showed signs of progression.
Study endpoints
The primary outcome was the composite rate of genitourinary side effects measured using validated patient questionnaires [15] [16] [17] .
Incontinence was defined using a score of 1-3 for question 1 (any leak) and of 1-3 for question 5 (any pad use) of the University of 2.5.
Statistical analysis
The sample size was calculated on a composite endpoint defined as the total proportion of men with erectile dysfunction and/or incontinence. It was estimated that baseline incontinence was about 10% and baseline impotence about 40% in men older than 60 yr [18, 19] . Overall, we estimated that baseline genitourinary dysfunction would be approximately 50%. Were these men to undergo whole-gland therapy, 50% of those with good baseline function would also suffer some form of genitourinary dysfunction [20] , so total genitourinary dysfunction would be approximately 75% at 12 mo if men were to undergo whole-gland therapy. It was hypothesised that focal therapy would give rise to genitourinary dysfunction in only 5% of those with good baseline function. Therefore, we estimated a total genitourinary dysfunction level of approximately 55% at 12 mo after focal index lesion ablation. Using sample size calculations comparing an estimate proportion (0.55) to a known proportion (0.75), with a = 0.05 and power of 90%, the total number of patients required was 56 [21] .
A Wilcoxon signed rank test (two-tailed) was used to evaluate However, some functional measures were missing at baseline or at 12-mo follow-up for five men, so we conducted two sensitivity analyses to assess if this was likely to impact our results. We repeated the analysis described above for a ''best'' outcome scenario and a ''worst'' outcome scenario by setting missing baseline values to the maximum or minimum possible, respectively.
Results
Study patients
Fifty-six men were recruited (July 27, 2009-January 26, 2011) with a mean age of 64 yr. According to National Comprehensive Cancer Network criteria [22] , seven men (12.5%) had low-risk, 47 (83.9%) had intermediate-risk, and two (3.6%) had high-risk nonmetastatic prostate cancer ( Fig. 1 , Table 1 ). In terms of absolute continence, the proportion of patients with pad-free continence fell from 54/54 (100%) at baseline to 50/54 (92.6%) at 12 mo, and the proportion of men with leak-free pad-free continence fell from 53/54 (98.1%) at baseline to 48/52 (92.6%) at 12 mo. In terms of relative continence, of the 52 patients with pad-free continence at baseline, 48 (92.3%; 95% CI 81.5-97.9%) remained so at 12 mo. Of 50 patients with a leak-free, pad-free status at baseline, 46 (92.0%; 95% CI 80.8-97.8%) remained so at 12 mo ( Supplementary Figs. 1-3 ).
Erectile function
In terms of absolute erectile function, the proportion of patients with erections sufficient for penetration decreased from 41/54 (75.9%) to 36/54 (66.7%) at 12 mo. PDE5-I use increased from 7/55 (12.7%) to 23/54 (42.6%).
In terms of relative erectile function, of 39 men with erections sufficient for penetration at baseline, 30 (76.9%; 95% CI 60.7-88.9%) remained so at 12 mo ( Supplementary  Figs. 4 and 5 ).
Health-related quality-of-life scores
Treatment appeared to have very little impact on generic health-related quality of life, both within the early postoperative period and at final follow-up ( p = 0.52; Supplementary Fig. 7 ).
Adverse events
There were no patient deaths and no serious adverse events. Nine men (16.1%) had transient, self-resolving dysuria (with a negative urine culture), 36/56 (64.3%) had intermittent self-resolving haematuria, and 24/56 (42.9%) had urinary passage of debris. Ten patients (17.9%) had a postoperative urinary tract infection (confirmed by positive urine culture). One man (1.8%) underwent resection of an area at the bladder neck that was suspicious on 6-mo mpMRI, which was subsequently diagnosed as Gleason 4 + 4 prostate cancer. Two men (3.6%) underwent a bladder neck incision. One further man (1.8%) underwent rigid cystoscopic resection of retained necrotic prostatic tissue causing recurrent urinary tract infections ( Table 2) . 
Biochemical, imaging, and histological outcomes
A significant decrease in serum PSA from a median baseline value of 7.4 ng/ml (IQR 5.6-9.5) to 2.4 ng/ml (IQR 1.6-4.1) was observed at 12 mo ( p < 0.0001; Fig. 3 ). At 6 mo, two men refused a post-treatment biopsy, and another two had clinical reasons for omitting biopsies (chemotherapy for newly diagnosed lung cancer in one, and a persistent HIFU cavity connecting with the vas deferens on mpMRI in another). For these four men, mpMRI at 6 mo showed no evidence of measurable residual disease. There was no histological evidence of clinically significant disease (Gleason 3 + 3, CCL 3 mm) in the treated area in 44/52 patients (84.6%; 95% CI 70-92%), or of any cancer in the treated area in 34/52 patients (65.4%; 95% CI 52.5-78.3%). Two had clinically significant disease on biopsies from suspicious areas in the untreated side on mpMRI not present at baseline. Overall, histopathological absence of clinically significant cancer (treated and untreated sides) was observed in 42/52 men (80.8%, 95% CI 67.5-90.4%). The overall rate of absence of measurable disease was 86% (48/56) at the study end following repeat treatment in two patients. However, 43% of men had persistent cancer of any threshold at the study end. Two other men underwent salvage treatment with neoadjuvant hormone ablation therapy and external beam radiotherapy for residual Gleason 4 + 3 and Gleason 4 + 4 disease (Table 3) .
Of 41 patients with good baseline status, 22 (53.7%, 95% CI 37.4-69.3%) achieved the trifecta outcome (absence of clinically significant disease, pad-free, leak-free continence, and erections sufficient for intercourse) at 12 mo (Fig. 4) . The results for sensitivity analyses (data not shown) were very similar and did not affect our overall conclusion.
Discussion
In this first attempt to limit prostate cancer treatment to the index lesion, the majority of men returned to baseline genitourinary function and 86% of men were free of clinically significant prostate cancer at the study end.
Our study has some limitations. First, the study size was relatively small. It was powered to give reasonable precision for the key endpoints so that a comparative effectiveness study could be planned [15] . A pilot randomised controlled trial (RCT) of focal therapy versus radical therapy to determine whether recruitment is possible has recently been funded in the UK [23] . Second, compared to most other studies of focal therapies, we relaxed the risk stratification methods to reflect changing practice. This meant that as well as using TPM plus mpMRI, we permitted entry to the study if a TRUS-guided biopsy proved to be concordant with mpMRI. We feel that this was the right decision, as there is now a substantial body of evidence supporting a high negative predictive value for mpMRI (95%) in ruling out prostate cancer with Gleason 7 and/or lesion volume 0.5 ml [24, 25] . This is in fact the performance characteristic seen with TPM [26] . This might be consistent with our results, since we detected two cases of clinically significant cancer in untreated areas at follow-up. These lesions might have been missed at baseline by the inherent 5% false-negative rate of mpMRI and TPM, although progression of untreated cancer lesions may also have occurred. However, we also acknowledge that there may be bias introduced in allowing TRUS biopsy with mpMRI concordance, as the more detailed histological mapping proffered by TPM biopsies may lead to different cancer control outcomes. The disease control rates by method of cancer localisation were as follows. For the 26 men undergoing TPM biopsies, 3/26 (11.5%; 95% CI 3.2-29.8%) had histological presence of clinically significant cancer in the treated area and 1/26 (3.8%; 95% CI 0.01-20.5%) had histological presence of clinically significant cancer in untreated areas. For the TRUS biopsy group of 22 men, these proportions were 5/22 (22.7%; 95% CI 9.7-43.8%) and 1/22 (4.5%; 95% CI 0.01-23.5%), respectively. Although this subgroup analysis demonstrates that TRUS biopsy may yield important clinical differences in histological outcomes, the difference between these proportions was not statistically significant. Third, our study population is likely to have limited external validity. We estimated a 10% baseline incontinence rate and a 40% baseline rate of erectile dysfunction, yet our data reveal rates of 0% and 24%, respectively. We applied no selection criteria, but it is likely that patients who were continent and on the whole had better than average erectile function at diagnosis sought out focal therapy in this trial in the hope of gaining access to a treatment that might preserve their function. Fourth, while our initial rate of endoscopic intervention (5.4%) within the first year is low, with further follow-up and potentially further repeat treatments, this rate might increase. This is clearly an issue that needs to be considered if focal therapy is recommended as standard care in the future. Fifth, while we report the overall rate of the absence of clinically significant disease as the primary cancer control measure to reflect the study design and rationale, it must be remembered that 43% of men had persistent disease at the study end. These men may exhibit progression with time.
Clinical implications
The outcome from other focal therapy studies in which treatment was applied to all known cancer lesions was recently reviewed [9] . Rates of 95-100% for pad-free, leakfree continence preservation, 54-100% for potency, and 83-100% for overall absence of clinically significant cancer were observed after treatment. Most of these studies applied strict selection criteria for disease risk, biopsy cancer burden, and function at baseline, and therefore have limited external validity. In our current study-in a group of men who were not selected by the investigators on the basis of good baseline function-the functional preservation outcomes were not as high as we have previously reported. Indeed, our trifecta rate is also lower than previously reported, and may not be as encouraging when compared to the rates reported after surgery. With greater numbers in our ongoing larger multicentre trials, we may be to identify men who are unlikely to have good functional outcomes after focal therapy and would be better treated using a radical approach. Our study is unique in that known cancer of low malignant potential was left untreated. We recently showed that if such a strategy were to be adopted, more than 90% of newly diagnosed men with localised prostate cancer might be eligible for focal therapy [27] . Some have argued that because mpMRI and TPM biopsies are not accurate enough to detect all areas of prostate cancer, the concept of selective therapy lacks legitimacy [28] . However, in most other solid organs, cancer is diagnosed when a clinical manifestation of disease (a lump or an imaging signal) is verified histologically. Inevitably, therapy is directed at the clinical phenotype plus the addition of a margin. This was recently seen in the administration of radiotherapy to the breast after lumpectomy. Historically, whole-breast irradiation was favoured because of the known multifocality of breast cancer. The finding that intraoperative local irradiation of the surgical site was not inferior to wholebreast irradiation challenges the idea that recurrence is due to residual subclinical multifocal lesions away from the index lesion [29] . There is also concern that inclusion of intermediate-and high-risk cases for focal therapy may represent undertreatment for those men who harbour microscopic nodal metastases.
It is yet to be determined whether an RCT of focal therapy compared to radical therapy is deliverable [23] . Previous trials have attempted to compare different interventions in localised prostate cancer; however, many have failed because of a lack of physician and patient equipoise. There are additional concerns regarding appropriate endpoints and the follow-up time frame, especially as a minimum of 10-yr follow-up would be required to evaluate metastases and mortality. The UK National Institute of Health Research has recently funded a pilot RCT to determine whether recruitment might be feasible (ISRCTN99760303). This RCT will evaluate rates of transition to local salvage therapies within a 5-yr period between focal therapy and radical prostatectomy in men with intermediate-risk prostate cancer.
Our findings have implications for prostate cancer management. Some have suggested that low-risk disease should be relabelled as a benign entity because of the rarity of progression and metastases from these lesions [10] [11] [12] . If this hypothesis proves to be true, we could concentrate on targeting measurable disease based on mpMRI considering the high negative predictive values for clinically significant disease that it confers. However, the notion that Gleason 6 disease cannot metastasise has recently been brought into question following the findings of Haffner et al [30] , who reported on a case in which a small area of Gleason 6 disease within a tumour of very high-grade cancer was responsible for a distant metastasis. There has been considerable debate regarding the validity of these findings [31] .
Our study also represents an in vivo human model for better understanding of the determinants of progression of low-grade disease in a manner that is not predicated on removing the whole organ. This might allow us to determine if such lesions do progress and, if so, whether they can be identified at the time of diagnosis using detailed molecular typing approaches such as immunohistochemistry and -omics techniques.
Conclusions
Prostate cancer is multifocal in the majority of men. Current treatment options deal with such multifocality by applying treatment to the entire gland, and this can lead to urinary incontinence and impotence in some men. It has been shown that treatment targeted to the index lesion is feasible, safe, and well tolerated, with high rates of genitourinary functional preservation. Comparative effectiveness studies are needed.
